Mark C. Scholz
Prostate Oncology Specialists
Prostate Institute of America
University of California at Los Angeles
Ashland Community Hospital
California
Name/email consistency: high
- Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study. Scholz, M.C., Groom, M.K., Kaddis, A.J., Strum, S.B., Jennrich, R.I., Bahn, D.K., Chang, P.J., Becker, L.K., Lam, R.Y. Prostate (2013)
- Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz, M., Lam, R., Strum, S., Jennrich, R., Johnson, H., Trilling, T. Urology (2007)
- Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H.J., Guess, B.W., Lam, R.Y. J. Urol. (2006)
- Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. Scholz, M., Jennrich, R., Strum, S., Brosman, S., Johnson, H., Lam, R. J. Urol. (2005)